JPRN-UMIN000002632已完成未知
Clinical pharmacology study of anti-estrogen based on pharmacogenomics and pharmacokinetics for hormone-sensitive breast cancer patients (JBCRG-15) - JBCRG-15 (PGx-PK based clinical pharmacology study of anti-estrogen)
JBCRG(Japan Breast Cancer Research Group)0 个研究点目标入组 14 人开始时间: 2009年11月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
TOR activity increased significantly with dose escalation, even among poor TAM metabolizers, and was maintained for >=24 weeks. TOR might be a valid alternative to TAM in patients predicted to be poor TAM metabolizers.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •History of thromboembolism Clinically significant myoma uteri Requiring CYP3A4 inhibitor Clinically significant co-morbidity Pregnant or its posibility
研究者
相似试验
已完成
2 期
ER Reactivation Therapy for Breast CancerMetastatic Breast CancerNCT02188745Dartmouth-Hitchcock Medical Center19
终止
3 期
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerBreast NeoplasmsNeoplasms, Hormone-DependentNCT00097344Intarcia Therapeutics842
已完成
3 期
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerBreast NeoplasmsNeoplasms, Hormone-dependentNCT00044291Intarcia Therapeutics865
已完成
2 期
Toremifene in Treating Patients With Desmoid TumorsDesmoid TumorNCT00002595Advocate Lutheran General Hospital72
终止
2 期
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell CarcinomaSquamous Cell CarcinomaNCT01009203New Mexico Cancer Care Alliance13